WHITEHAWK THERAPEUTICS, INC. Amortization of Debt Issuance Costs
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Amortization of Debt Issuance Costs of $75.56 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2019-03-07
- WHITEHAWK THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2017-06-30 was $0.00.
- WHITEHAWK THERAPEUTICS, INC. amortization of debt issuance costs for the quarter ending 2017-03-31 was $75.56K.
- WHITEHAWK THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2017 was $75.56K, a 59.95% decline from fiscal 2016.
- WHITEHAWK THERAPEUTICS, INC. amortization of debt issuance costs for fiscal 2016 was $188.69K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $75.56K 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $75.56K 10-Q · filed 2018-11-07 | $145.69K derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $75.56K 10-Q · filed 2018-08-14 | $145.69K derived: sum of 3 quarters · filed 2018-08-14 | $204.97K derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $75.56K 10-Q · filed 2018-05-15 | $145.69K derived: sum of 2 quarters · filed 2018-05-15 | $204.97K derived: sum of 3 quarters · filed 2018-05-15 | |
| 2016-12-31 | $70.13K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $129.41K derived: sum of 2 quarters · filed 2018-03-15 | $188.69K 10-K · filed 2018-03-15 | |
| 2016-09-30 | $59.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $118.55K 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | $59.28K 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |